New Zealand - engelsk - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - capecitabine 150mg;   - film coated tablet - 150 mg - active: capecitabine 150mg   excipient: croscarmellose sodium hypromellose lactose magnesium stearate microcrystalline cellulose opadry pink 03a14309 - xeloda is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated. xeloda in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - capecitabine 500mg;   - film coated tablet - 500 mg - active: capecitabine 500mg   excipient: croscarmellose sodium hypromellose lactose magnesium stearate microcrystalline cellulose opadry pink 03a14380 - xeloda is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated. xeloda in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

apotex nz ltd - capecitabine 150mg - film coated tablet - 150 mg - active: capecitabine 150mg excipient: colloidal silicon dioxide croscarmellose sodium hyprolose hypromellose iron oxide red iron oxide yellow lactose macrogol 8000 magnesium stearate methylcellulose titanium dioxide - breast cancer capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated. capecitabine in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. colon cancer capecitabine is indicated for the adjuvant treatment of patients with dukes' stage c and high risk stage b colon cancer, either as monotherapy or in combination with oxaliplatin. colorectal cancer capecitabine is indicated for first-line treatment of patients with metastatic colorectal cancer. oesophagogastric cancer capecitabine is indicated for the first line treatment of patients with advanced oesophagogastric cancer in combination with a platinum-based regimen.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

apotex nz ltd - capecitabine 500mg - film coated tablet - 500 mg - active: capecitabine 500mg excipient: colloidal silicon dioxide croscarmellose sodium hyprolose hypromellose iron oxide red iron oxide yellow lactose macrogol 8000 magnesium stearate methylcellulose titanium dioxide - breast cancer capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated. capecitabine in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. colon cancer capecitabine is indicated for the adjuvant treatment of patients with dukes' stage c and high risk stage b colon cancer, either as monotherapy or in combination with oxaliplatin. colorectal cancer capecitabine is indicated for first-line treatment of patients with metastatic colorectal cancer. oesophagogastric cancer capecitabine is indicated for the first line treatment of patients with advanced oesophagogastric cancer in combination with a platinum-based regimen.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

dr reddy's new zealand limited - capecitabine 150mg - film coated tablet - 150 mg - active: capecitabine 150mg excipient: croscarmellose sodium hypromellose opadry pink 03a540004 lactose magnesium stearate microcrystalline cellulose - capercit tablets are indicated for the adjuvant treatment of patients with dukes stage c and higher-risk stage b colon cancer, either as monotherapy or in combination with oxaloplatin

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

dr reddy's new zealand limited - capecitabine 500mg - film coated tablet - 500 mg - active: capecitabine 500mg excipient: croscarmellose sodium hypromellose opadry pink 03a540003 lactose magnesium stearate microcrystalline cellulose - capercit tablets are indicated for the adjuvant treatment of patients with dukes stage c and higher-risk stage b colon cancer, either as monotherapy or in combination with oxaloplatin

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - capecitabine 150mg - film coated tablet - 150 mg - active: capecitabine 150mg excipient: croscarmellose sodium hypromellose lactose magnesium stearate microcrystalline cellulose opadry pink 03a84408 purified water - capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated. capecitabine in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - capecitabine 500mg - film coated tablet - 500 mg - active: capecitabine 500mg excipient: croscarmellose sodium hypromellose lactose magnesium stearate microcrystalline cellulose opadry pink 03a84598 purified water - capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated. capecitabine in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

Sør-Afrika - engelsk - South African Health Products Regulatory Authority (SAHPRA)

equity pharmaceutical (pty) ltd - tablet - see ingredients - each tablet contains capecitabine 150,0 mg

Sør-Afrika - engelsk - South African Health Products Regulatory Authority (SAHPRA)

equity pharmaceutical (pty) ltd - tablet - see ingredients - each tablet contains capecitabine 500,0 mg